-
Tytuł:
-
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.
-
Autorzy:
-
Cazzaniga M; Research Unit Phase I trials, ASST Monza, Monza, Italy.; Oncology Unit, ASST Monza, Monza, Italy.
Verusio C; Oncology Unit, ASST della Valle Olona-Presidio Ospedaliero di Saronno, Saronno, Italy.
Ciccarese M; Oncology Unit, Ospedale 'Vito Fazzi' di Lecce, Lecce, Italy.
Fumagalli A; Oncology Unit, Ospedale Moriggia Pelascini, Gravedona, Italy.
Sartori D; Oncology Unit, AULSS 3, Mirano, Italy.
Valerio MR
Ancona C; Oncology Department, Policlinico di Palermo Paolo Giaccone, Palermo, Italy.
Airoldi M; Oncology Unit 2-Città della Salute e della Scienza di Torino, Torino, Italy.
Moretti G; Oncology Unit, IRCCS Arcispedale S. Maria Nuova, Reggio Emilia, Italy.
Ficorella C; Dipartimento di Scienze Cliniche Applicate e Biotecnologiche (DISCAB)-Università Degli Studi Dell'Aquila, L'Aquila, Italy.
Arcangeli V; Oncology Unit Rimini Azienda USL Romagna, Rimini, Italy.
Diodati L; Oncology Unit 2, Azienda Osp edaliera Universitaria Pisa via Roma 67, Pisa, Italy.
Zambelli A; Oncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.
Febbraro A; Oncology Unit, Ospedale Sacro Cuore di Gesù, Fatebenefratelli, Benevento, Italy.
Generali D; Brest Unit, ASST di Cremona, Cremona, Italy.
Pistelli M; Oncology Unit, AOU Ospedali Riuniti Umberto I-GM Lancisi-G Salesi, Ancona, Italy.
Garrone O; Oncology Unit, AOS Croce e Carle Ospedale di Insegnamento, Cuneo, Italy.
Musolino A; Oncology Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
Vici P; Oncology Unit 2, Istituto Nazionale Tumori Regina Elena-IFO, Roma, Italy.
Maur M; Oncology Unit, Policlinico University Hospital of Modena, Modena, Italy.
Mentuccia L; Oncology Unit, ASL di Frosinone Osp. 'SS. Trinità', Sora, Italy.
La Verde N; Oncology Unit, ASST Fatebenefratelli Sacco Presidio Ospedaliero Fatebenefratelli, Milano, Italy.
Bianchi G; Oncology Unit 1, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy.
Artale S; Oncology Departement, Ospedale di Gallarate ASST Valle Olona, Gallarate, Italy.
Blasi L; Oncology Unit, ARNAS Civico Palermo, Palermo, Italy.
Piezzo M; National Cancer Institute 'Fondazione Giovanni Pascale', Napoli, Italy.
Atzori F; Struttura Complessa di Oncologia Medica Azienda Ospedaliero-Universitaria Cagliari, Italy.
Turletti A; Oncology Unit, Ospedale Martini della ASL Città di Torino, Torino, Italy.
Benedetto C; Dipartimento Universitario Ginecologia e Ostetricia 1, Ospedale S. Anna Torino, Turin, Italy.
Cursano MC; Oncology Unit, Università Campus Bio-Medico, Roma, Italy.
Fabi A; Oncology Unit 1, Istituto Regina Elena-IFO, Roma, Italy.
Gebbia V; Oncology Unit, Ospedale La Maddalena, Palermo, Italy.
Schirone A; Oncolgy Department, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Palumbo R; Oncology Unit, IRCCS ICS Maugeri, Pavia, Italy.
Ferzi A; Oncology Unit, ASST OVEST Milanese, Presidio di Legnano, Legnano, Italy.
Frassoldati A; Oncology Unit, Az Ospedaliero Universitaria di Ferrara, Ferrara, Italy.
Scavelli C; Oncology Unit, Ospedale 'S. Cuore di Gesù', Gallipoli, Italy.
Clivio L; IRCCS-Istituto di Ricerche Farmacologiche 'Mario Negri', Milano, Italy.
Torri On Behalf Of The Eva Study Group V; IRCCS-Istituto di Ricerche Farmacologiche 'Mario Negri', Milano, Italy.
-
Źródło:
-
Oncotarget [Oncotarget] 2018 Aug 07; Vol. 9 (61), pp. 31877-31887. Date of Electronic Publication: 2018 Aug 07 (Print Publication: 2018).
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: Albany, N.Y. : Impact Journals
-
References:
-
Ann Oncol. 2016 Sep;27(9):1719-25. (PMID: 27358383)
N Engl J Med. 2012 Feb 9;366(6):520-9. (PMID: 22149876)
Lancet Oncol. 2012 Apr;13(4):e148-60. (PMID: 22469125)
Lancet Oncol. 2017 May;18(5):654-662. (PMID: 28314691)
Breast Cancer Res Treat. 2018 Feb;167(3):607-614. (PMID: 29103175)
N Engl J Med. 2016 Nov 3;375(18):1738-1748. (PMID: 27717303)
CMAJ Open. 2013 Nov 07;1(4):E134-41. (PMID: 25077115)
J Oncol Pract. 2008 Jul;4(4):162-8. (PMID: 20856765)
Clin Breast Cancer. 2013 Dec;13(6):421-432.e8. (PMID: 24267730)
Eur Urol. 2012 Apr;61(4):826-33. (PMID: 22297244)
J Clin Epidemiol. 1995 Dec;48(12):1503-10. (PMID: 8543964)
N Engl J Med. 2016 Nov 17;375(20):1925-1936. (PMID: 27959613)
J Clin Oncol. 2017 Feb;35(4):421-431. (PMID: 27992272)
Breast. 2017 Oct;35:115-121. (PMID: 28711793)
Ann Oncol. 2014 Apr;25(4):808-15. (PMID: 24615500)
-
Contributed Indexing:
-
Keywords: advanced breast cancer; elderly; everolimus; exemestane; hormone-receptor positive
-
Entry Date(s):
-
Date Created: 20180831 Latest Revision: 20191120
-
Update Code:
-
20240105
-
PubMed Central ID:
-
PMC6112755
-
DOI:
-
10.18632/oncotarget.25874
-
PMID:
-
30159129
-
Background: The present analysis focuses on real-world data of Everolimus-Exemestane in advanced HR+ve, HER2-ve elderly breast cancer patients (aged 65 years) included in the EVA study, with unique findings in those aged 70 years.
Methods: Data are collected from clinical records and analysed according to age cut-off (< 65 years; 65 - 69 years and {greater than or equal to} 70 years). Relationship of analyzed variables with response were tested by mean of a Mantel-Haenszel chi square test. Time to event analysis was described by Kaplan Meier approach and association with baseline characteristics was analysed by stratified log-rank test and proportional hazard model.
Results: From July 2013 to December 2015, the EVA study enrolled overall 404 pts. 154 patients out of 404 (38,1%) were aged {greater than or equal to} 65 years, of whom 87 were {greater than or equal to} 70 years. Median duration of EVE treatment was 28.5 weeks (95% CI 19.0 - 33.8) in patients aged 65-69 years and 24,4 weeks (95% CI 19,2 - 33,2) in those aged {greater than or equal to} 70 years. Fewer patients aged 65 years received the highest EVE Dose-Intensity (>7.5 mg/day) in comparison to younger patients (49,6% vs. 66,8%). Grade 3-4 toxicities occurred to 55 patients (35,7%), mainly stomatitis (10,9%), rash (5,8%) and non-infectious pneumonitis (NIP) (3,6%). Some toxicities, such as weight loss and anaemia were peculiarly observed in patients aged {greater than or equal to} 70 years. Five treatment-related deaths were collected (3,2%).
Conclusions: EVE-EXE combination remains one of the potential treatments in HR+ patients also for elderly ones.
Competing Interests: CONFLICTS OF INTEREST The Authors declare that they have no conflicts of interest.
Erratum in: Oncotarget. 2018 Oct 2;9(77):34639-34640. Valerio, Maria Rosario [added]. (PMID: 30349655)
Erratum in: Oncotarget. 2018 Nov 30;9(94):36720-36721. (PMID: 30613355)
